GI
NSAID Gastrointestinal Adverse Effects
search
NSAID Gastrointestinal Adverse Effects
See Also
NSAID
NSAID
Alternatives
Risk Factors
NSAID
related GI adverse effects
Age over 60 years (decreased GI protection)
Peptic Ulcer Disease
history
Concurrent
Corticosteroid
use
Concurrent oral
Anticoagulation
(
Coumadin
,
Aspirin
)
High dose
NSAID
Risk Factors
Relative Risk
s of GI adverse effects
Lowest Risk:
COX2 Inhibitor
s (Selective)
Celecoxib
(
Celebrex
)
Rofecoxib
(
Vioxx
)
Low Risk (Non-Selective
NSAID
s)
Ibuprofen
(
Relative Risk
1.0 to 2.7)
Fenoprofen
or
Nalfon
(
Relative Risk
1.6)
Aspirin
(
Relative Risk
1.6)
Diclofenac
or
Voltaren
(
Relative Risk
1.8 to 4.0)
Sulindac
or
Clinoril
(
Relative Risk
2.1)
Nabumetone
or
Relafen
(more COX-2 specific)
Etodolac
or
Lodine
(more COX-2 specific)
Salsalate
Medium Risk
Diflunisal
or
Dolobid
(
Relative Risk
2.2)
Naproxen
or
Naprosyn
(
Relative Risk
2.2 to 5.2)
Indomethacin
or
Indocin
(
Relative Risk
2.4 to 5.3)
Tolmetin
or
Tolectin
(
Relative Risk
3.0)
Meloxicam
or
Mobic
(
Relative Risk
4.0)
Despite being touted as more COX-2 specific
High Risk
Piroxicam
or
Feldene
(
Relative Risk
3.8 to 9.3)
Ketoprofen
or
Orudis
(
Relative Risk
4.2 to 5.7)
Azapropazone (
Relative Risk
9.2)
Flurbiprofen
or
Ansaid
Ketorolac
or
Toradol
(
Relative Risk
14.0)
Adverse Effects
Gastroduodenal Ulcer
Incidence
by endoscopy (12 weeks)
Naprosyn
: 35%
Ibuprofen
: 23-29% (2 different trials)
Diclofenac
: 10%
Rofecoxib
: 5-8% (25-50 mg)
Celecoxib
: 7%
Placebo
: 4-7% (2 different trials)
References
(1999) Med Lett Drugs Ther 41(1045): 11-14 [PubMed]
Laine (1999) Gastroenterology 116:A229 [PubMed]
Management
Prophylaxis
Gene
ral
Always use
NSAID
with food or milk
COX2 Inhibitor
s have no advantage over standard
NSAID
Consider screening for
Helicobacter Pylori
before use
Indications for prophylaxis (avoid
NSAID
s if possible)
Age over 75 years
Concurrent
Warfarin
therapy
History of
Peptic Ulcer Disease
History of
Gastrointestinal Bleeding
History of
Coronary Artery Disease
Misoprostol
(
Cytotec
)
Dose: 100-200 ug tid to qid
Replaces
Prostaglandin
s at
Stomach
lining
Allows use of
NSAID
S in
Peptic Ulcer Disease
Causes significant dose limiting
Diarrhea
Sucralfate
Ineffective at preventing
NSAID
related
Peptic Ulcer
s
H2 Receptor Antagonist
s (e.g.
Zantac
,
Tagamet
)
Not recommended (may mask GI symptoms)
Prevents
Duodenal Ulcer
, not
Gastric Ulcer
Consider high dose
H2 Antagonist
Omeprazole
Heals, but may not protect from formation
References
Henry (1996) BMJ 312:1563-6 [PubMed]
(1999) Med Lett Drugs Ther 41(1045): 11-14 [PubMed]
Masso (2010) Arthritis Rheum 62(6): 1592-1601 [PubMed]
Type your search phrase here